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In this issue of Chemistry & Biology, Belitsky et al. [1] elegantly describe the use of supramolecular
complexes of sugars to multivalently target Galectin-1 (Gal-1), a lectin involved in the organization
of cell surface glycoproteins, signaling, cell death, and cancer metastasis.The images of proteins and nucleic
acids in biochemistry textbooks are
often adapted from crystal structures
or Irving Geiss illustrations. These im-
ages, however, represent only single
frames in a movie. In reality, biomole-
cules are dynamic and exhibit motions
that are either stochastic or carefully
orchestrated, as in cases of chemical
catalysis. On a larger scale, this dy-
namic nature is also illustrated by the
constant reorganization of proteins
and lipids on cell surfaces.
Carbohydrates displayed on cell
surfaces are essential for signaling and
adhesion, but they are also gateways
for viral and bacterial infections. The
hallmark of these interactions is multi-
valency, in which multiple weak inter-
actions are formed simultaneously to
increase affinity and specificity. Taking
cues from nature, many laboratories
have used multivalency as a strategy
to find inhibitors of a variety of interac-
tions, including those between a virus
and a host cell by multivalently dis-
playing sugars on a polymer’s back-
bone [2]. In some cases, crystal struc-
tures of carbohydrates bound to their
receptors can guide the design of
multivalent compounds, illustrated by
the elegant work of the Bundle group
to neutralize Shiga-like toxins by
STARFISH ligands [3].
The most common multivalent as-
semblies used to target cell surface
interactions display ligands on flexible
polymeric scaffolds. The flexible na-
ture of the scaffolds is advantageous
since it allows some conformational
flexibility in how multivalent ligands
are displayed. These flexible poly-
mers, however, do not exhibit flexibility
on a scale that would allow them toadapt toward the dynamic distribution
of glycoproteins on cell surfaces. Be-
cause of the weak monovalent affinity
of carbohydrates and lectins (Kds R
1 mM) and the use of multivalency to
increase binding affinity, the impacts
of cell surface dynamics on molecular
recognition are likely to be significant.
In this issue of Chemistry & Biology,
Belitsky et al. [1] elegantly describe
the use of adaptable supramolecular
pseudopolyrotaxanes that multiva-
lently display mobile ligands, analo-
gous to ‘‘beads on a string.’’ The li-
gands have rotational freedom about
the polymer and limited translational
freedom. This allows the ligands to op-
timally orient themselves with regard
to the target and to each other (Fig-
ure 1). Specifically, they used pseudo-
polyrotaxanes displaying lactosides to
multivalently target galectin-1 (Gal-1),
which normally binds glycoproteins
expressed on cell surfaces. Informa-
tion from studies of a series of sugar-
displaying pseudopolyrotaxanes gives
insight into the optimal spacing be-
tween ligands and ligand adaptability.
Galectins play important roles in cell
adhesion, signaling, angiogenesis, and
apoptosis. Thus, galectins have long
been an intriguing target for the
development of cancer therapeutics.
Specifically, intra- and extracellular
Gal-1 contribute to tumor progression
through cell adhesion and migration
and to tumor escape from the immune
system. Gal-1 is overexpressed in
cancer cells and binds to lactosides
expressed on the surfaces of T cells
causing their aggregation and even-
tual apoptosis. This leads to the weak-
ened immune response that is asso-
ciated with tumor progression andChemistry & Biology 14, October 2007 ª2metastasis. Interestingly, inhibition of
Gal-1 gene expression suppresses tu-
mor proliferation [4] and is associated
with improved immunoregulation and
a corresponding decrease in tumor
mass [5]. These results suggest that
inhibition of Gal-1 may be a viable ther-
apeutic avenue for treatment of cancer.
Like other cell surfaces, the organi-
zation of proteins expressed on T cell
surfaces is dynamic. Despite this,
Gal-1 effectively binds lactosides dis-
played on the cell surface and nucleate
T cell agglutination. Thus, the coau-
thors hypothesized that multivalently
displayed lactosides that mimic dy-
namic reorganization at T cell surfaces
might bind in a similar fashion and be
effective inhibitors of Gal-1. An addi-
tional challenge to multivalently target-
ing Gal-1 is the protein itself. Like other
members of its protein superfamily,
Gal-1 is a rigid dimer [6] with two lacto-
side binding sites that are spaced far
apart and point in opposite directions.
Belitsky and coworkers showed that
pseudopolyrotaxanes can dynamically
display lactosides, accommodate dis-
tal binding sites, and inhibit T cell
agglutination (Figure 1) [1].
The pseudopolyrotaxane system
used to multivalenlty target Gal-1 was
based on the pioneering work of
Harada [7] and Wenz [8] on cyclodex-
trin (CD)-based pseudopolyrotaxanes.
Belitsky et al. [1] used a polyviologen
backbone encircled by cyclodextrin
(CD) functionalized with lactosides
(LCD). Polyviologen copolymers are re-
peating units of decamethylene and
positively charged bipyridinium units.
CDs are naturally occurring cyclic oli-
gosaccharides that encircle hydropho-
bic compounds in aqueous solutions.007 Elsevier Ltd All rights reserved 1095
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Schematics of (A), T cell agglutination caused by the lactoside binding protein Galactin-1 (Gal-1) and (B), inhibition of T cell agglutination by adaptable
pseudopolyrotaxanes that display lactoside-functionalized cyclodextrins (LCDs). LCDs can rotate 360 about the polymer and have limited transla-
tional freedom.The LCDs have both translational and
rotational freedom around the polymer
backbone. They can rotate 360, how-
ever, their translational movement is
limited by the presence of the bipyri-
dium units, which serve as ‘‘speed
bumps.’’
In order to determine the optimal
length of the polymer backbone (re-
lated to the distance between binding
sites) and the loading of LCDs (related
to multivalent binding), the authors
synthesized and studied three poly-
mers. By altering the amount of poly-
mer present in a constant concentra-
tion of LCDs, the amount of loading
or threading was controlled. Nearly
fully threaded polymers were synthe-
sized by adding equimolar amounts
of LCDs to repeating polymer units.
Analogously, half-threaded and quar-1096 Chemistry & Biology 14, October 20ter-threaded polymers were created
by having twice the amount of polymer
repeating units as LCDs and four times
the amount of polymer, respectively.
Fully threaded pseudopolyrotaxane
with one equivalent of free LCD were
created from solutions containing a 2:1
ratio of LCD:polymer repeating units.
The polymers were then tested for
their ability to inhibit T cell agglutina-
tion and compared to the monovalent
lactoside-functionalized CD. At 100
mM concentration of lactoside, the
longest polymer with quarter thread-
ing showed the largest multivalent
enhancement over monovalent lac-
tose (30-fold) and free LCD (20-fold)
and was 2-fold better than the fully
threaded polymer. This is consistent
with a supramolecular statistical ef-
fect, in which multivalent binding is de-07 ª2007 Elsevier Ltd All rights reservedpendent on the number of connected
ligands. Though the lactosides dis-
played on the pseudopolyrotaxanes
are not covalently connected, they are
mechanically connected by encapsu-
lating the same polymer backbone.
Though there are still some ques-
tions to be answered such as the
mechanism of binding, these studies
are a firm foundation for future investi-
gations that use adaptable ligands to
multivalently bind other biomolecules.
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